Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial
MMT for newly diagnosed high-risk localized and low-volume metastatic prostate cancer is feasible, safe, and provides a rapid readout of efficacy. A significant proportion of patients, including those with oligometastatic disease, maintained an undetectable PSA following T-recovery at the 2-year endpoint. These results have informed the design of an adaptive trial using MMT on a continuous basis to prioritize effective approaches for further study.
Authors
- Matthew C. Dallos (ORCID: https://orcid.org/0000-0002-5412-3490)
- Eric A. Klein (ORCID: https://orcid.org/0000-0002-1783-0698)
- Anuradha Gopalan (ORCID: https://orcid.org/0009-0007-6017-0991)
- Christopher Gaffney (ORCID: https://orcid.org/0000-0002-7785-6611)
- Sean Matthew McBride (ORCID: https://orcid.org/0000-0002-9676-1669)
- Paul Linh Nguyen (ORCID: https://orcid.org/0000-0003-4268-3973)
- Shilpa Gupta (ORCID: https://orcid.org/0000-0002-8775-503X)
- Hannah Benoliel (ORCID: https://orcid.org/0009-0009-8639-6440)
- Deaglan Joseph McHugh (ORCID: https://orcid.org/0000-0003-1477-0105)
- James Eastham (ORCID: https://orcid.org/0000-0001-6359-8378)
- Mary‐Ellen Taplin (ORCID: https://orcid.org/0000-0002-3384-0300)
- Sean Sachdev (ORCID: https://orcid.org/0000-0001-7682-9673)
- Min Yuen Teo (ORCID: https://orcid.org/0000-0003-2511-6731)
- Andres Martin Acosta (ORCID: https://orcid.org/0000-0001-8817-6331)
- Patrick McCann (ORCID: https://orcid.org/0000-0002-1836-4617)
- David Johnson Einstein (ORCID: https://orcid.org/0000-0001-9163-3281)
- Andrew A. Wagner (ORCID: https://orcid.org/0000-0002-1832-1983)
- Alvin C. Goh (ORCID: https://orcid.org/0000-0003-3092-9024)
- Glenn J. Bubley (ORCID: https://orcid.org/0000-0002-3062-643X)
- Scott E. Eggener (ORCID: https://orcid.org/0000-0001-6677-2503)
- Andrea Arfè (ORCID: https://orcid.org/0000-0003-1534-0609)
- Stanley L. Liauw (ORCID: https://orcid.org/0000-0002-4701-2469)
- William J. Catàlona (ORCID: https://orcid.org/0009-0004-2926-5114)
- Alicia Katherine Morgans (ORCID: https://orcid.org/0000-0002-6563-4587)
- Adam S. Kibel (ORCID: https://orcid.org/0000-0002-9446-7781)
- Howard I. Scher (ORCID: https://orcid.org/0000-0002-6791-9324)
- David James VanderWeele (ORCID: https://orcid.org/0000-0003-4576-5034)
- Russell Z. Szmulewitz (ORCID: https://orcid.org/0000-0002-1444-3617)
- Rahul D. Tendulkar (ORCID: https://orcid.org/0000-0002-6633-0577)
- Catherine Ryan (ORCID: https://orcid.org/0000-0003-1694-6426)
- Karen A. Autio (ORCID: https://orcid.org/0000-0003-0720-0390)
- Kevin M DeRudder (ORCID: https://orcid.org/0009-0002-5768-6288)
- Irving Kaplan (ORCID: https://orcid.org/0009-0006-9848-0509)
- Mehak Amjed (ORCID: https://orcid.org/0009-0008-0257-9198)
Institutions
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Cleveland Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Indianapolis (US)
- UCLA Health (US)
- Hadassah Medical Center (IL)
- Harvard University Press (US)
- Kettering University (US)
- University of Chicago (US)
- University of Chicago Medical Center (US)
- zuChem (United States) (US)
- Dana-Farber Cancer Institute (US)
- Grail (United States) (US)
- Dana-Farber Brigham Cancer Center (US)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2679
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00